CA19-9

CA19-9 is a type of tumor marker used in the detection and management of certain types of cancer, particularly pancreatic cancer. It is a glycoprotein that is produced by the cells in the pancreas and is elevated in the presence of pancreatic cancer.

Overview

CA19-9 is not used as a standalone diagnostic tool for pancreatic cancer, as it can also be elevated in other conditions such as liver disease, gallstones, and inflammation of the pancreas. However, it can be useful in monitoring the progress of pancreatic cancer treatment and in predicting the prognosis of the disease.

Function

CA19-9 is a type of antigen that is produced by the cells in the pancreas. It is released into the bloodstream and can be detected through a blood test. The level of CA19-9 in the blood can provide information about the presence and progression of pancreatic cancer.

Clinical Use

CA19-9 is primarily used in the management of pancreatic cancer. It can be used to monitor the effectiveness of treatment, with decreasing levels indicating a positive response to treatment. It can also be used to detect recurrence of the disease after treatment.

Limitations

While CA19-9 can be a useful tool in the management of pancreatic cancer, it has several limitations. It is not specific to pancreatic cancer and can be elevated in other conditions. Additionally, not all individuals with pancreatic cancer will have elevated CA19-9 levels. Therefore, it should not be used as a standalone diagnostic tool.

See Also

• Tumor marker
• Pancreatic cancer
• Glycoprotein
• Antigen
• Blood test

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia